Arrowhead Pharmaceuticals, Inc. Free Cash Flow 2003–2025
Arrowhead Pharmaceuticals, Inc. reported $156.89M of free cash flow for fiscal 2025. That was 126.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +245.6%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $156.89M | +126.0% |
| FY 2024 | $-604.32M | -82.8% |
| FY 2023 | $-330.63M | -75.0% |
| FY 2022 | $-188.91M | -227.9% |
| FY 2021 | $147.75M | +237.1% |
| FY 2020 | $-107.75M | -166.9% |
| FY 2019 | $161.03M | +431.0% |
| FY 2018 | $-48.64M | -52.7% |
| FY 2017 | $-31.86M | +53.3% |
| FY 2016 | $-68.29M | -0.9% |
| FY 2015 | $-67.68M | -82.3% |
| FY 2014 | $-37.13M | -92.1% |
| FY 2013 | $-19.33M | -22.2% |
| FY 2012 | $-15.82M | -106.4% |
| FY 2011 | $-7.67M | -51.7% |
| FY 2010 | $-5.05M | — |
| FY 2009 | $0 | — |
| FY 2008 | $0 | — |
| FY 2007 | $0 | — |
| FY 2006 | $0 | — |
| FY 2005 | $0 | — |
| FY 2004 | $0 | — |
| FY 2003 | $0 | — |
Source: Arrowhead Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ARWR 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Arrowhead Pharmaceuticals, Inc. reported $156.89M of free cash flow for fiscal 2025. That was 126.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +245.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Arrowhead Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeArrowhead Pharmaceuticals, Inc. — frequently asked questions
What is Arrowhead Pharmaceuticals, Inc.'s free cash flow?
Arrowhead Pharmaceuticals, Inc. (ARWR) reported free cash flow of $156.89M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Arrowhead Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.